Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

Completed · Phase 2

Conditions studied: Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma

In brief

This is a phase 2b, randomized, open-label, prospective, multicenter study comparing treatment with INNO 206 to doxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who have not been previously treated with any chemotherapy except potentially as adjuvant or neoadjuvant chemotherapy, and no evidence of tumor recurrence has occurred for at least 12 months.

Key facts

Study ID

NCT01514188

Run by

ImmunityBio, Inc.

People needed

126

Starts

2012-01-11

Expected to finish

2014-12-15

Last updated by the study team

2024-05-29

Who can join

Age: 15 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age between 15-80 years (US only), and 18-80 (rest of world (ROW)), male or female.
• Adjuvant or neoadjuvant chemotherapy (including doxorubicin) allowed if no tumor recurrence for at least 12 months since the last measurement, beginning or end of last chemotherapy.
• Histologically or cytologically confirmed, locally advanced, unresectable, and/or metastatic soft tissue sarcoma of intermediate or high grade.
• Capable of providing informed consent and complying with trial procedures.
• ECOG performance status 0-2.
• Life expectancy > 12 weeks.
• Measurable tumor lesions according to RECIST 1.1 criteria.
• Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. (Adequate contraception includes: oral contraception, implanted contraception, intrauterine device implanted for at least 3 months, or barrier method in conjunction with spermicide.)
• Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating.
• Geographic accessibility to the site that ensures the subject will be able to keep all study-related appointments.

You may not qualify if…

• Prior chemotherapy unless for adjuvant or neoadjuvant therapy with no tumor recurrence for at least 12 months.
• Prior exposure to > 3 cycles or 225 mg/m2 of doxorubicin or Doxil®.
• Palliative surgery and/or radiation treatment less than 4 weeks prior to Randomization.
• Exposure to any investigational agent within 30 days of Randomization.
• Current Stage 1 or 2 soft tissue sarcomas.
• Current evidence/diagnosis of alveolar soft part sarcoma, chondrosarcoma, rhabdomyosarcoma, osteosarcoma, gastrointestinal stromal tumor (GIST), dermatofibrosarcoma, Ewing's sarcoma, Kaposi's sarcoma, mixed mesodermal tumor, clear cell sarcomas and unresectable low grade liposarcomas.
• Central nervous system metastasis
• History of other malignancies except cured basal cell carcinoma, superficial bladder cancer or carcinoma in situ of the cervix unless documented free of cancer for > 5 years.
• Laboratory values: Screening serum creatinine > 1.5x upper limit of normal (ULN), alanine aminotransferase (ALT) > 3 × ULN or >5 × ULN if liver metastases are present, total bilirubin > 3 × ULN, absolute neutrophil count < 1,500/mm3, platelet concentration < 100,000/mm3, hematocrit level < 25% for females or < 27% for males, or coagulation tests (prothrombin time [PT], partial thromboplastin time [PTT], International Normalized Ratio [INR]) > 1.5 × ULN, albumin < 2.0 g/dL.
• Clinically evident congestive heart failure > class II of the New York Heart Association (NYHA) guidelines.
• Current, serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V.
• Baseline QTc > 470 msec and/or previous history of QT prolongation while taking other medications. Concomitant use of medications associated with a high incidence of QT prolongation is not allowed.
• History or signs of active coronary artery disease with or without angina pectoris.
• Serious myocardial dysfunction defined as scintigraphically (e.g. MUGA, myocardial scintigram) or ultrasound determined absolute left ventricular ejection fraction (LVEF) < 45% of predicted.
• History of HIV infection.
• Active, clinically significant serious infection requiring treatment with antibiotics, anti-virals or anti-fungals.
• Major surgery within 3 weeks prior to Randomization.
• Substance abuse or any condition that might interfere with the subject's participation in the study or in the evaluation of the study results.
• Any condition that is unstable and could jeopardize the subject's participation in the study.

Where it is running

• Sarcoma Oncology Center — Santa Monica, California, United States
• Stanford University — Stanford, California, United States
• University of Iowa — Iowa City, Iowa, United States
• Pennsylvania Hematology Oncology Associates — Philadelphia, Pennsylvania, United States
• CTRC Institute for Drug Development, University of Texas — San Antonio, Texas, United States
• Royal North Shore — St Leonards, New South Wales, Australia
• Epworth HealthCare Clinical Trials and Research Centre — Richmond, Victoria, Australia
• Border Medical Oncology — Wodonga, Victoria, Australia
• Royal Hobart Hospital — Hobart, Australia
• Royal Perth Hospital — Perth, Australia
• Mount Medical Centre — Perth, Australia
• The Crown Princess Mary Cancer Centre Westmead — Sydney, Australia
• State Health Centre Oncology Department — Budapest, Hungary
• Hemato Oncology Clinic, Vedanta Institute of Medical Science — Thaltej, Ahmedaba, India
• Hemato Oncology Clinic, Vedanta Institute of Medical Science — Ahmedabad, Gujarat, India
• M.S. Ramaiah Medical College and Hospitals — Bangalore, Karnataka, India
• Curie Manavata Cancer Centre — Nashik, Maharashtra, India
• Delhi State Cancer Institute — Pune, Maharashtra, India
• Jehangir Clinical Development Centre Pvt Ltd — Pune, Maharashtra, India
• Delhi State Cancer Institute — Mandoli, National Capital Territory of Delhi, India
• Noble Hospital Clinical Research Department 1st Floor — Hadapsar, Pune Maharashtra, India
• Christian Medical College — Vellore, Tami Nadu, India
• Tata Memorial Hospital, Department of Medical Oncology — Mumbai, India
• Oncological Institute "Prof. Dr. I. Chiricuta", Cluj-Napoca — Cluj-Napoca, County Cluj, Romania
• Clinical County Hospital Mures, Medical Oncology Department — Târgu Mureş, County Mures, Romania

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.